← Back to Screener
Viatris Inc. Common Stock (VTRS)
Price$14.87
Favorite Metrics
Price vs S&P 500 (26W)43.92%
Price vs S&P 500 (4W)3.75%
Market Capitalization$17.31B
Indicated Dividend Yield (Annual)3.23%
All Metrics
P/CF (Annual)7.48x
Book Value / Share (Quarterly)$12.78
P/TBV (Annual)9.50x
Indicated Dividend (Annual)$0.48
Revenue Growth (3Y)-4.20%
Cash Flow / Share (Quarterly)$1.61
Payout Ratio (TTM)137.04%
Price vs S&P 500 (YTD)15.51%
Gross Margin (TTM)39.55%
Net Profit Margin (TTM)-24.58%
EPS (TTM)$-2.96
10-Day Avg Trading Volume8.58M
EPS Excl Extra (TTM)$-2.96
Revenue Growth (5Y)3.66%
EPS (Annual)$-3.00
Dividend / Share (Annual)$0.48
ROI (Annual)-12.07%
Gross Margin (Annual)39.55%
Net Profit Margin (5Y Avg)-4.57%
Cash / Share (Quarterly)$1.24
Revenue Growth QoQ (YoY)4.97%
ROA (Last FY)-9.45%
Revenue Growth TTM (YoY)-2.98%
EBITD / Share (TTM)$-0.34
ROE (5Y Avg)-4.67%
Operating Margin (TTM)-19.34%
Cash Flow / Share (Annual)$1.61
P/B Ratio1.18x
P/B Ratio (Quarterly)0.97x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.13x
Net Interest Coverage (TTM)-6.78x
ROA (TTM)-9.25%
EV / EBITDA (TTM)10.78x
EPS Incl Extra (Annual)$-3.00
Current Ratio (Annual)1.38x
Quick Ratio (Quarterly)0.70x
3-Month Avg Trading Volume9.81M
52-Week Price Return96.69%
EV / Free Cash Flow (Annual)16.43x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.31
P/S Ratio (Annual)1.21x
Asset Turnover (Annual)0.38x
52-Week High$16.47
Operating Margin (5Y Avg)-1.79%
EPS Excl Extra (Annual)$-3.00
CapEx CAGR (5Y)-7.35%
Tangible BV CAGR (5Y)29.84%
26-Week Price Return50.81%
Quick Ratio (Annual)0.70x
13-Week Price Return15.81%
Total Debt / Equity (Annual)0.98x
Current Ratio (Quarterly)1.38x
Enterprise Value$30,403.04
Revenue / Share Growth (5Y)-9.28%
Asset Turnover (TTM)0.38x
Book Value / Share Growth (5Y)-7.64%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.20x
Pretax Margin (Annual)-25.63%
Cash / Share (Annual)$1.24
3-Month Return Std Dev35.51%
Gross Margin (5Y Avg)40.95%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)0.43%
EBITDA Interim CAGR (5Y)43.73%
ROE (Last FY)-23.89%
Net Interest Coverage (Annual)-6.78x
EPS Basic Excl Extra (Annual)$-3.00
P/FCF (TTM)9.36x
Receivables Turnover (TTM)5.44x
EV / Free Cash Flow (TTM)16.43x
Total Debt / Equity (Quarterly)0.98x
EPS Incl Extra (TTM)$-2.96
Receivables Turnover (Annual)5.44x
ROI (TTM)-11.85%
P/S Ratio (TTM)1.21x
Pretax Margin (5Y Avg)-2.99%
Revenue / Share (Annual)$12.21
Tangible BV / Share (Annual)$1.31
Forward P/E6.09x
Free OCF CAGR (5Y)27.44%
Price vs S&P 500 (52W)62.06%
Year-to-Date Return19.44%
5-Day Price Return6.90%
EPS Normalized (Annual)$-3.00
ROA (5Y Avg)-1.80%
Net Profit Margin (Annual)-24.58%
Month-to-Date Return10.07%
Cash Flow / Share (TTM)$3.97
EBITD / Share (Annual)$-0.34
Operating Margin (Annual)-19.34%
LT Debt / Equity (Annual)0.85x
P/CF (TTM)7.48x
ROI (5Y Avg)-2.33%
LT Debt / Equity (Quarterly)0.85x
EPS Basic Excl Extra (TTM)$-2.96
P/TBV (Quarterly)9.50x
Payout Ratio (Annual)28.47%
P/B Ratio (Annual)0.97x
Dividend / Share (TTM)$0.48
Inventory Turnover (TTM)2.20x
Pretax Margin (TTM)-25.63%
Book Value / Share (Annual)$12.78
Price vs S&P 500 (13W)13.43%
Dividend Yield (TTM)3.24%
Beta0.89x
P/FCF (Annual)9.36x
Revenue / Share (TTM)$12.41
ROE (TTM)-22.99%
52-Week Low$7.39
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.61
3.72
3.83
3.83
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VTRSViatris Inc. Common Stock | 1.21x | -2.98% | 39.55% | — | $14.87 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Viatris is a globally diversified pharmaceutical company formed in November 2020 through the merger of Pfizer's Upjohn division and Mylan, establishing itself as one of the world's largest generic drug manufacturers serving over 165 countries. The company generates approximately 60% of revenues from established pharmaceutical products including Lipitor, Norvasc, Lyrica, and Viagra, while the remaining 40% comes from generic drugs and biosimilars. Viatris operates across over 10 therapeutic areas, with strategic focus on dermatology, ophthalmology, and gastroenterology for future growth.